LONG BEACH, Calif., Feb. 27, 2025 /PRNewswire/ — Anivive, a software-driven pet health company, announces their sponsorship of the 69th Annual Coccidioidomycosis Study Group on April 4-5, 2025 hosted by Arizona State University and Mayo Clinic at the ASU Health Futures Center in Phoenix, AZ.
In additional to financial support for the meeting, Anivive is providing $50,000 in Travel Awards to cover airfare and lodging for up to 25 eligible Study Group attendees.
Since 2017, Anivive has partnered with the Valley Fever Center for Excellence at the University of Arizona, to advance their live-vaccine candidate through preclinical and clinical studies for veterinary use. In August 2024, Anivive secured a $33 million contract from the National Institute of Allergy and Infectious Diseases, to support adapting their canine vaccine for human use, with the potential to be the world’s first vaccine against a systemic fungal infection.
“Anivive is proud to provide ongoing support to these world-renowned experts in fungal disease,” said Dylan Balsz, Anivive CEO. “Our dedication extends beyond this initiative—we have made significant progress with our Valley fever program and this meeting brings together many of our partners to tackle the challenges faced in bringing fungal vaccines, therapeutics and diagnostics to market.”
To learn more about Anivive’s Valley Fever vaccine visit https://www.anivive.com/valley-fever
About Anivive Lifesciences
Anivive Lifesciences is a software-driven pet pharmaceutical company at the forefront of biotechnology, artificial intelligence, and veterinary medicine. Our mission is to transform veterinary healthcare by accelerating the development of novel, affordable treatments for life-threatening diseases in pets. Through our proprietary AI platform, we are pioneering first-in-class therapeutics in Oncology, Antivirals, and Antifungal Vaccines, setting new standards for innovation and excellence in the industry. To learn more, visit anivive.com
About Coccidioidomycosis Study Group
The Coccidioidomycosis Study Group was created in San Francisco, California on July 18, 1956. This group oversees conferences, annual meetings and research studies. Much of the documented knowledge of the pathogenesis, mycology and clinical aspects of Coccidioidomycosis originated from studies performed by this research group. To learn more, visit https://coccistudygroup.org/
SOURCE Anivive Lifesciences Inc.
GARLAND, Texas, Feb. 3, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo" or the "Company"),…
Next-Generation Decision Support Software Introduces Predictive Clinical Tools for Gastroenterology, Rheumatology, Dermatology, and PulmonologyFORT MYERS,…
After making personal health accessible to millions with Fitbit, James Park and Eric Friedman announce…
COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full…
The collaboration positions the UAE as a global leader in conservation, driving pioneering initiatives in…
New York, New York--(Newsfile Corp. - February 3, 2026) - Case Reports in Regrowth today…